Steqeyma

Drug Overview

Navigating life with a chronic autoimmune condition often means searching for treatments that offer long-lasting relief and healing. In the field of Immunology, significant advancements have been made in developing medications that target the root causes of inflammation. One of the most important developments in recent years is the introduction of highly effective biosimilar medications.

Steqeyma is a prescription medication belonging to the Drug Class of Interleukin Inhibitors. It is a highly advanced Biologic medication and serves as an FDA-approved biosimilar to the well-known reference drug, Stelara (ustekinumab). A biosimilar is a medication that is highly similar to an original biologic, with no clinically meaningful differences in safety, purity, or effectiveness. By acting as a precise Targeted Therapy, Steqeyma helps to regulate an overactive immune system, providing a pathway to remission for patients facing severe inflammatory bowel diseases and other chronic conditions.

• Generic Name: Ustekinumab-aekn
• US Brand Names: Steqeyma
• Drug Category: Immunology
• Drug Class: Interleukin Inhibitor (Specifically, IL-12 and IL-23 inhibitor)
• Route of Administration: Intravenous (IV) infusion (typically for the first starting dose in bowel diseases) and Subcutaneous (under the skin) injection.
• FDA Approval Status: Fully FDA-approved for specific adult autoimmune conditions, matching the primary indications of its reference product.

What Is It and How Does It Work? (Mechanism of Action)

To understand how Steqeyma provides relief, it helps to understand what goes wrong in an autoimmune disease. In conditions like Crohn’s disease and ulcerative colitis, the immune system becomes confused and launches a continuous, unprovoked attack on healthy tissues in the digestive tract. This harmful attack is coordinated by specific chemical messengers in the body called cytokines.

Steqeyma is a highly specialized Monoclonal Antibody. This means it is a targeted protein created in a laboratory designed to find and attach to one specific molecular structure in the body. The specific target for Steqeyma is a protein subunit called “p40.” This p40 building block is shared by two major inflammatory cytokines: Interleukin-12 (IL-12) and Interleukin-23 (IL-23).

Normally, IL-12 and IL-23 travel through the body and bind to receptors on the surface of immune cells, such as T-cells and Natural Killer cells. When they connect, it acts like a biological alarm bell, activating the Th1 and Th17 immune pathways. These pathways are directly responsible for causing severe tissue swelling, deep ulcerations in the intestines, and red, scaly plaques on the skin.

By binding directly to the p40 subunit, this Targeted Therapy physically intercepts IL-12 and IL-23 before they can ever reach the immune cells. Because the signal to trigger inflammation is blocked at the molecular and cellular level, the immune system is effectively “calmed down.” This selective cytokine inhibition stops the inflammatory cascade, allowing the body to naturally repair the intestinal lining, clear the skin, and soothe aching joints.

FDA-Approved Clinical Indications

This potent Immunomodulator is approved to treat multiple systemic inflammatory diseases. By modulating the immune response, it prevents widespread, systemic tissue damage across different organ systems.

Primary Immunology Indications

• Crohn’s Disease (CD): Approved for adults with moderately to severely active Crohn’s disease. It is used in this category to modulate the localized immune response in the digestive tract, reducing severe intestinal inflammation, stopping abdominal pain, and promoting deep mucosal healing of the bowel lining.
• Ulcerative Colitis (UC): Approved for adults with moderately to severely active ulcerative colitis. It specifically targets the inflammatory cytokines causing damage in the large intestine (colon) and rectum, halting bleeding, reducing chronic diarrhea, and preventing permanent scarring of the colon.

Other Approved & Off-Label Uses

Because it works on fundamental inflammatory pathways, Steqeyma is also utilized for other related conditions:

• Plaque Psoriasis: Approved for adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis (PsA): Approved for adult patients with active psoriatic arthritis, helping to prevent irreversible joint damage.
• Off-Label Uses: Specialists may sometimes explore its use in severe, treatment-resistant cases of atopic dermatitis (eczema) or certain inflammatory eye conditions (uveitis), though these are not its primary, officially approved indications.

Dosage and Administration Protocols

Dosing for this Biologic is uniquely tailored based on the specific condition being treated and the patient’s body weight. For digestive diseases like Crohn’s and UC, treatment begins with a larger “induction dose” given through an IV to quickly gain control of the disease, followed by smaller “maintenance doses” given as shots under the skin.

Important Dose Adjustments and Considerations:

• Transition to Maintenance: The transition from the IV induction dose to the subcutaneous maintenance dose is a critical period. The first under-the-skin injection must happen exactly 8 weeks after the IV infusion to maintain steady drug levels in the blood.
• Elderly Patients: While no specific mathematical dose reductions are strictly required for patients over 65, closer clinical monitoring is essential due to a naturally higher risk of infections in older populations.
• Patients with Underlying Infections: If a patient develops a serious active infection (such as pneumonia or a severe skin infection), the scheduled dose of Steqeyma must be held until the infection is completely treated and resolved.

Clinical Efficacy and Research Results

The approval of Steqeyma is supported by clinical data (2020–2026) confirming its biosimilarity to the reference drug, showing equivalent efficacy, safety, and purity to Stelara.

Gastrointestinal Indications
Clinical studies of ustekinumab products show strong efficacy in Crohn’s disease and ulcerative colitis:

• High rates of clinical remission and mucosal healing
• Sustained remission at one year after initial IV response
• Significant reductions in inflammatory markers (CRP, ESR)

Dermatology & Rheumatology
Plaque Psoriasis: ~70% of patients achieve PASI 75 within 12 weeks.
Psoriatic Arthritis: ~50% achieve ACR20 response by week 24, with improved physical function.

Safety Profile and Side Effects

Because Steqeyma modulates the immune system, it carries risks that require medical supervision. While it has no Black Box Warning, it includes FDA warnings for infections and certain malignancies.

Common Side Effects (>10%)

• Upper respiratory tract infections (e.g., common cold, sinusitis)
• Nasopharyngitis (sore throat, nasal congestion)
• Headache, mild dizziness, fatigue
• Injection site reactions (redness, itching, swelling)

Serious Adverse Events
Opportunistic Infections: Increased susceptibility to bacterial, viral, and fungal infections, including reactivation of latent tuberculosis (TB).
Malignancies: Slight increased risk of certain cancers, especially non-melanoma skin cancers.
RPLS: Rare neurological condition causing headaches, seizures, confusion, and vision changes.
Non-infectious Pneumonia: Rare but serious lung inflammation requiring discontinuation and treatment.

Management Strategies

To prevent severe complications, strict screening protocols are used prior to treatment. If mild allergic reactions occur during injections, doctors often recommend “pre-medication” with over-the-counter antihistamines or acetaminophen. If a patient contracts a significant illness, a “wash-out” period is utilized, meaning the biologic is paused to let the immune system recover and fight the infection using standard antibiotics before resuming the Targeted Therapy.

Research Areas

Immunology (2020–2026) is shifting with biosimilars like Steqeyma, improving access to affordable biologics and enabling safe switching from reference drugs. Research focuses on interchangeability, genetic biomarkers for precision immunology, and targeted IL-12/23 therapy. Early intervention studies suggest potential to prevent severe, multi-organ damage and reduce surgeries in diseases like Crohn’s by halting progression early.

Clinical disclaimer

This information should be treated as evidence-based but not definitive. Statements implying guaranteed safe switching, exact biomarker-based response prediction, or reliable prevention of surgery and multi-organ damage should be interpreted cautiously unless supported by direct clinical evidence. Biosimilars such as Steqeyma may improve access to IL-12/23 therapy, but individual outcomes depend on disease severity, prior treatment history, and patient-specific response.

Clinical disclaimer

This information should be treated as evidence-based but not definitive. Statements implying guaranteed safe switching, exact biomarker-based response prediction, or reliable prevention of surgery and multi-organ damage should be interpreted cautiously unless supported by direct clinical evidence. Biosimilars such as Steqeyma may improve access to IL-12/23 therapy, but individual outcomes depend on disease severity, prior treatment history, and patient-specific response.

Patient Management and Clinical Protocols

• Managing chronic illness with an immunomodulator like Steqeyma requires close patient–doctor coordination.
• Pre-treatment Assessment
  Baseline Diagnostics: TB screening (QuantiFERON or PPD), Hepatitis B/C tests.
  Organ Function: CBC and metabolic panel with liver tests.
  Screening: Vaccinations updated before therapy.
• Monitoring & Precautions
  Vigilance: Watch for infection signs; routine bloodwork and skin exams.
  Lifestyle: Anti-inflammatory diet, hydration, stress control.
• Do’s & Don’ts
  DO: Refrigerate medication, report symptoms, inform all healthcare providers.
  DON’T: Take live vaccines or stop therapy without medical advice.

Legal Disclaimer

The medical information provided in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, specialist immunologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, prescription medication, or treatment plan. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.